LENSAR, Inc. announced its third quarter 2024 financial results on November 7, 2024, reporting total revenue of $13.5 million, a 38% increase compared to $9.8 million in the third quarter of 2023. This growth was driven by increased system sales and procedure volumes across all revenue categories.
The company placed 24 ALLY Robotic Laser Cataract Systems in Q3 2024, including 11 sales in the European Union and Southeast Asia following regulatory certifications in August 2024. Worldwide procedure volumes increased by 29% over the third quarter of 2023, contributing to a total installed base of approximately 355 systems.
LENSAR achieved positive Adjusted EBITDA of $0.4 million for the quarter, a significant improvement from ($1.4) million in the prior year period. The company's U.S. market share for premium procedures reached 19.9% as of September 30, 2024, reflecting a 3.5% gain in the past year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.